Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 804 participants.

Also called NCT04289285

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 804 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04289285
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04289285. Randomized; quadruple masking; primary purpose treatment. Start 2020-04-29 (actual); primary completion 2022-02-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia
Condition
Hypercholesterolemia
Intervention (Drug)
IBI306 450mg SC Q4W
Intervention (Drug)
Placebo SC Q4W
Intervention (Drug)
IBI306 600mg SC Q6W
Intervention (Other)
Placebo SC Q6W
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04289285
Content hash
2326643068d935775af9a64ed570adb15ed4b444bc5f7bfb8304b3556acc4b49